Open-Label Study To Evaluate the Safety & Efficacy of the Renal Assist

Status Completed

Clinical Trial Summary

Although conventional hemodialysis removes waste products and corrects fluid imbalance, it does not replace critical absorptive, metabolic, endocrine, and immunologic functions performed by healthy renal tubule cells. This trial involving patients with acute renal failure evaluates the efficacy and safety of an extracorporeal renal assist device (RAD) containing human renal tubule cells connected to a conventional hemodialysis circuit. It is hypothesized that short-term (72-h) use of this cell therapeutic device will improve survival of ARF patients compared to patients receiving only conventional continuous renal replacement therapy.

Clinical Trial Description

Acute Renal Failure (ARF) is a severe inflammatory disease state often accompanied by Multi-Organ Failure (MOF) and Systemic Inflammatory Response Syndrome (SIRS). ARF is precipitated by many factors and is most often linked to the loss of kidney tubule cell function. Patients with ARF are treated in the intensive care units of hospitals, and recovery of renal function is vitally important to their survival. Current therapy for ARF involves conventional kidney support with continuous renal replacement therapies (CRRT). Despite advances in treating patients with CRRT, ARF has an extremely high mortality rate (55-70%) and requires extensive hospital stays, predominantly in the ICU. The RAD is designed to both treat ARF with MOF and/or SIRs and facilitate the natural recovery of a patient's own kidney function. The RAD is intended for use for short periods of time in conventional extracorporeal therapeutic systems that are already available in the hospital. The RAD therapy operates outside the body and is designed to mimic the structure and function of the natural kidney. In this manner it is intended to replace the missing metabolic, endocrine, and immunologic functions of the kidney and allow time for the patient's own kidneys to resume normal functions. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00511407
Study type	Interventional
Source	RenaMed Biologics
Contact
Status	Completed
Phase	Phase 2
Start date	March 2004
Completion date	August 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01946113` - Mineral-Homeostasis in Continuous Renal Replacement Therapy	N/A
Withdrawn	`NCT00993733` - Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care	N/A
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Terminated	`NCT00978354` - Furosemide in Early Acute Kidney Injury	Phase 2/Phase 3
Completed	`NCT00120263` - Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma	N/A
Completed	`NCT04799600` - The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
Recruiting	`NCT04334707` - Kidney Precision Medicine Project
Completed	`NCT02858531` - Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
Recruiting	`NCT05282732` - Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
Completed	`NCT01467466` - Prevention of Serious Adverse Events Following Angiography	Phase 3
Completed	`NCT01979042` - Urinary Markers for Unilateral Kidney Obstruction	N/A
Completed	`NCT01280617` - Low Dose Thymoglobin in Renal Transplant Patients	N/A
Completed	`NCT00780351` - Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)	N/A
Completed	`NCT00971971` - Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients	N/A
Completed	`NCT00076219` - Acute Renal Failure Trial Network (ATN) Study	Phase 3
Recruiting	`NCT04599569` - Influence of Renal Replacement TherApy on Indirect Calorimetry
Completed	`NCT03727204` - Acute Kidney Injury After Cardiac Surgery: Novel Ultrasound Techniques for Prediction of Acute Kidney Injury
Completed	`NCT06005896` - A Clinical Model for Dialysis Discontinuation in AKI
Completed	`NCT03004950` - Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)
Completed	`NCT03627884` - Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Open-Label Study To Evaluate the Safety and Efficacy of the Renal Assist Device In Patients With Acute Renal Failure

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms